Pharmacyclics LLC, an AbbVie company, will host a presentation on IMBRUVICA® (ibrutinib) during the ASH Annual Meeting.
On December 1st, 2022
Pharmacyclics LLC, invites you to attend a Multidisciplinary Discussion during the 2022 ASH Annual Meeting on Incorporating Imbruvica® (ibrutinib) into treatment strategies. The program will be held on Monday December 12th from 8:00 to 9:00 AM in Exhibit Hall/Theater 7 during the ASH Annual Meeting. Session sponsored by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
TO RSVP, GO TO: https://portal.meintl.com/s/janssen-hcp-program?program=P0001907
Please note: Your e-mail address is required for registration. The information you provide will only be used to facilitate your attendance at this program.
Pharmacyclics LLC, invites you to attend a Multidisciplinary Discussion during the 2022 ASH Annual Meeting on Incorporating Imbruvica® (ibrutinib) into treatment strategies. The program will be held on Monday December 12th from 8:00 to 9:00 AM in Exhibit Hall/Theater 7 during the ASH Annual Meeting. Session sponsored by Pharmacyclics LLC, an AbbVie company and Janssen Biotech, Inc.
TO RSVP, GO TO: https://portal.meintl.com/s/janssen-hcp-program?program=P0001907
Please note: Your e-mail address is required for registration. The information you provide will only be used to facilitate your attendance at this program.
No comments have been posted yet.